NCT04731610 (RADIO-RYTHMIC) is a NA clinical trial of Radiotherapy in Thymoma Malignant Recurrent, sponsored by Institut Curie.

Who is sponsoring NCT04731610?

NCT04731610 is sponsored by Institut Curie.

What drugs are being tested in NCT04731610?

Interventions in NCT04731610: Radiotherapy, Surveillance after resection.

What condition does NCT04731610 study?

NCT04731610 studies Thymoma Malignant Recurrent.

Is NCT04731610 still recruiting?

NCT04731610 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT04731610: RADIO-RYTHMIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

Recruiting now NA Last updated 2 February 2026

What this trial tests

NA trial testing Radiotherapy in Thymoma Malignant Recurrent in 314 participants. Currently enrolling.

Timeline

28 December 2021

Primary endpoint
28 December 2031

28 December 2032

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	314
Start date	28 December 2021
Primary completion	28 December 2031
Estimated completion	28 December 2032
Sites	20 locations across France

Drugs / interventions tested

Radiotherapy — full drug profile →
Surveillance after resection

Conditions studied

Thymoma Malignant Recurrent — all drugs for Thymoma Malignant Recurrent →

Sponsor

Institut Curie — full company profile →

Who can join

Adults 18 to 75, any sex, with Thymoma Malignant Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
Remon J, Bernabé R, Diz P, Felip E, et al · · 2022 · cited 12× · PMID 35122634 · DOI 10.1007/s12094-022-02788-w
Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice.
Loap P, Vitolo V, Barcellini A, De Marzi L, et al · · 2021 · cited 2× · PMID 34707989 · DOI 10.3389/fonc.2021.738320

Verify or expand the search:

Other trials of Radiotherapy

Trials testing the same drug.

NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04731610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing